NDAORALCAPSULE, TABLET, TABLETPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA TRIPLE PAK is a fixed-dose combination oral therapy containing vonoprazan fumarate (a potassium-competitive acid blocker), amoxicillin, and clarithromycin for Helicobacter pylori eradication. This triple therapy addresses a major unmet need in H. pylori treatment by combining a novel acid suppression mechanism with two established antibiotics. The regimen is designed to improve cure rates and treatment tolerability in patients with H. pylori infection.
Peak4.3 years to LOE
Product is in peak commercial phase with high competitive intensity (8/10), suggesting active brand team investment and market expansion initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOQUEZNA TRIPLE PAK at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.